Nucala 100mg Powder For Injection

• Severe eosinophilic asthma: Mepolizumab helps reduce eosinophil-related airway inflammation and lower the risk of asthma flare-ups in eligible patients aged six years and older.
• Eosinophilic chronic obstructive pulmonary disease: In selected adults, it may help reduce inflammation when standard inhaled treatment does not control symptoms adequately.
• Chronic sinus inflammation with nasal polyps: It may reduce eosinophil-driven inflammation and nasal polyp symptoms when prescribed for this condition.
• Eosinophilic granulomatosis with polyangiitis: This treatment may help reduce inflammatory symptoms and support disease control in eligible patients.
• Hypereosinophilic syndrome: It may reduce disease activity in selected patients with persistently high eosinophil levels.

• Headache: Head pain may occur after treatment and is often temporary. Rest and fluids may help, but report severe or persistent pain.
• Injection-site reaction: Pain, redness, swelling or itching can appear where the injection was given. Tell the nurse if the area becomes very painful or rapidly enlarges.
• Back pain: Aching in the back may occur after treatment. Seek advice if it is severe or accompanied by weakness.
• Fatigue: Feeling unusually tired can occur as the body adjusts. Avoid driving if tiredness affects concentration.
• Other common effects: Sore throat, joint pain, diarrhoea or cough may occur after treatment. Tell your doctor if any becomes severe or persistent.

• Keep using your prescribed inhalers unless your doctor changes the plan.
• Keep a written asthma action plan and know which treatment is for sudden symptoms.
• Avoid known asthma triggers where possible.
• Tell the clinic about fever, infection or parasitic illness before treatment.
• Get emergency medical help for severe breathlessness, blue lips or swelling of the face, lips or throat.

Overdose

Missed a Dose

Interactions with other medicines